Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Active:	No
Cancer Type:	Bile Duct Cancer Breast Cancer Colon/Rectal Cancer Head and Neck Cancer Lung Cancer Melanoma Neuroendocrine Tumor Ovarian Cancer Sarcoma	NCT ID:	NCT02568267
Trial Phases:	Phase II	Protocol IDs:	RXDX-101-02 (primary) NCI-2015-01848
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Hoffmann-La Roche
NCI Full Details:	http://clinicaltrials.gov/show/NCT02568267

Summary

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101)
for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK
gene fusion. Patients will be assigned to different baskets according to tumor type and
gene fusion.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.